Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14680269 | 0.98 | ALDH1A1 (0.39) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL14680298 | 0.93 | ALDH1A1 (0.32) | ALDH1A1MAPK1 | |
| SCHEMBL14680315 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL14680357 | 0.79 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL14680235 | 0.78 | GAA (0.33) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL14680249 | 0.77 | USP2 (0.34) | USP2LMNA | |
| SCHEMBL14680348 | 0.75 | USP2 (0.33) | ALDH1A1USP2LMNA | |
| SCHEMBL27437136 | 0.73 | ALDH1A1 (0.42) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL3999902 | 0.73 | FAAH (0.48) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL7105001 | 0.71 | ALDH1A1 (0.32) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TYMP, PIM1, TYMS | ALDH1A1 2328/4885KDM4E 911/4885USP2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.